Legal Advantage Investments Inc. Sells 200 Shares of Veeva Systems Inc. $VEEV

Legal Advantage Investments Inc. trimmed its stake in shares of Veeva Systems Inc. (NYSE:VEEV) by 1.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,155 shares of the technology company’s stock after selling 200 shares during the period. Veeva Systems makes up about 2.7% of Legal Advantage Investments Inc.’s investment portfolio, making the stock its 10th biggest position. Legal Advantage Investments Inc.’s holdings in Veeva Systems were worth $5,804,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of VEEV. GAMMA Investing LLC lifted its position in shares of Veeva Systems by 13.8% during the first quarter. GAMMA Investing LLC now owns 1,823 shares of the technology company’s stock worth $422,000 after purchasing an additional 221 shares in the last quarter. CX Institutional acquired a new position in Veeva Systems in the first quarter valued at approximately $308,000. Fifth Third Bancorp lifted its holdings in Veeva Systems by 5.0% in the first quarter. Fifth Third Bancorp now owns 8,970 shares of the technology company’s stock valued at $2,078,000 after buying an additional 429 shares during the period. Azzad Asset Management Inc. ADV acquired a new position in Veeva Systems in the first quarter valued at approximately $7,191,000. Finally, Capital Investment Services of America Inc. lifted its holdings in Veeva Systems by 0.8% in the first quarter. Capital Investment Services of America Inc. now owns 79,737 shares of the technology company’s stock valued at $18,469,000 after buying an additional 663 shares during the period. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Veeva Systems Stock Performance

VEEV opened at $287.04 on Friday. The firm’s fifty day moving average is $282.91 and its two-hundred day moving average is $265.06. The firm has a market cap of $47.05 billion, a PE ratio of 58.94, a price-to-earnings-growth ratio of 2.22 and a beta of 0.98. Veeva Systems Inc. has a twelve month low of $201.54 and a twelve month high of $310.50.

Veeva Systems (NYSE:VEEV) last posted its earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.90 by ($0.64). The firm had revenue of $789.08 million during the quarter, compared to analyst estimates of $768.49 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter last year, the business posted $1.62 earnings per share. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Equities analysts forecast that Veeva Systems Inc. will post 4.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Jonathan Faddis sold 720 shares of the stock in a transaction on Monday, October 6th. The shares were sold at an average price of $298.12, for a total transaction of $214,646.40. Following the completion of the sale, the senior vice president owned 7,868 shares of the company’s stock, valued at $2,345,608.16. This represents a 8.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas D. Schwenger sold 3,350 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the sale, the insider directly owned 23,773 shares of the company’s stock, valued at $7,132,850.92. This represents a 12.35% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,665 shares of company stock worth $7,438,000. Company insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on VEEV shares. Needham & Company LLC increased their price objective on shares of Veeva Systems from $300.00 to $355.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Wells Fargo & Company increased their price objective on shares of Veeva Systems from $300.00 to $326.00 and gave the company an “overweight” rating in a report on Tuesday, August 26th. Truist Financial increased their price objective on shares of Veeva Systems from $268.00 to $275.00 and gave the company a “hold” rating in a report on Thursday, August 28th. Citigroup increased their price objective on shares of Veeva Systems from $329.00 to $349.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Finally, Stifel Nicolaus increased their price objective on shares of Veeva Systems from $295.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Sixteen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $307.58.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.